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Abstract
The microbiome is composed of many organisms and is impacted by an intricate exchange between
genetics and environmental factors. The perinatal microbiome influences both the developing fetus
and the pregnant person. The purpose of this article is to describe the tests that are currently available
for laboratory analysis of the perinatal microbiome in relationship to probiotic interventions. This
article focuses on the bacterial component of the microbiome. Although adverse outcomes associated
with the perinatal microbiome have been studied, a comprehensive understanding of the physiologic
perinatal microbiome is still emerging. Early efforts to influence the perinatal microbiome
through probiotics are currently under investigation. Unique terminology is defined, and the microbial
composition of perinatal microbiota is summarized. The outcomes of studies of
antenatal probiotics are summarized. Microbiome testing and analysis are defined and compared.
Implications for perinatal care and probiotics research are presented.
The human microbiome is composed of microorganisms populating the human body, including
commensals, symbionts, and pathogens.1 The microbiome is impacted by an intricate exchange
between genetics and environmental factors.2 The perinatal microbiome influences nutrient
absorption, the intrauterine fetal environment, immune system priming, and long-term impacts on
health and illness of offspring. The diet and general health and well-being of the pregnant woman also
influence the perinatal microbiome.3–6
The focus of this article is the bacterial component of the microbiome and not the viruses,
bacteriophages, fungi, and archaea populating pregnant women. The term “microbiota” refers to the
collection of individual microbes present in a given sample or at a specified location, as well as their
genetic information or collective coding capacity. Sites studied to understand the perinatal microbiota
include the maternal oral, gastrointestinal (GI) and genitourinary tracts, as well as maternal skin and
breast. In the perinatal period, the microbiome has been studied in the context of pathology, such as
allergies, atopy, and dysbiosis.7–11 Adverse obstetrical outcomes, such as preterm labor and birth,
preterm premature rupture of membranes, intrauterine growth restriction, gestational diabetes,
stillbirth, and more, are believed to be linked to the perinatal microbiome12,13; yet, a comprehensive
understanding of the physiologic perinatal microbiome is still emerging. Knowledge of the genomes of
microorganisms, their hosts, and relationship to each other in specific environments continues to
rapidly develop.11,12,14
The purpose of this article is to describe the tests that are currently available for laboratory analysis of
the perinatal microbiome in relationship to probiotic interventions. First, a broad overview of terms is
presented. Second, probiotic interventions are described. Third, the microbial composition of perinatal
microbiota is summarized by collection site. Studies of antenatal probiotics are presented as they
relate to each of the sites. Fourth, both the microbiome testing and analysis are outlined. Finally,
implications for perinatal care and probiotics research are described.

TERMINOLOGY
The taxonomical terminology associated with the microbiome and microbial analysis is essential to
understanding relevant laboratory testing. Although nurses, midwives, and other perinatal clinicians
are exposed to this terminology in undergraduate education, for many, it has not become a part of

everyday practice. Table 1 provides terminology and definitions that serve as the foundation for an
understanding of both the perinatal microbiome and probiotic interventions.
Table 1. - Terminology used in microbiome-based research
Term
16S rRNA

Definition
A portion of the bacterial ribosome containing variable and
conserved regions. Widely used as a phylogenetic marker of a unique
population, including all of its descendents.15
Alpha diversity
Measures to address variation within a sample. Some measures take
only richness into account, whereas others assess diversity.
Common measures include Shannon,16 Simpson,17 ACE, and Chao1.18
Amplicon sequence variants Individual DNA sequences recovered from marker gene analysis
following removal of spurious chimeric sequences generated during
PCR amplification.19 May also be called exact sequence variants, subOTUs, and/or zero radius OTUs (zOTUs).
Archaea
Single-celled organisms structurally similar to bacteria, though
evolutionarily distinct. The role of archaea in human health requires
further investigations, though they likely play an important role.
Beta diversity
Measures how different composition is between 2 different samples,
groups, or environments. Common measures include the Bray-Curtis
dissimilarity,20 Jaccard distance,21 and UniFrac/Weighted UniFrac
measures.22
Clade
Organisms that descend and evolve from a common ancestor.
Commensal
Commensal organisms refer to the indigenous microorganisms
present at a given anatomical site. Microorganisms that have
coevolved with the host and have a symbiotic relationship with the
host. Also referred to as resident microbes.
Coverage depth
The average number of times a genome is sequenced. Calculated by
the number of bases of short reads matching a genome divided by
the length of the genome.
Diversity
A measurement of species richness and evenness. How many species
are present and how evenly distributed they are.15
Evenness
Describes the relative abundance of the species present in a sample;
distribution of species.
Facultative organisms
Those able to grow with and without oxygen.
Metabolomics
Study of the metabolite profiles in a sample or tissue. Can be
assessed using nuclear magnetic resonance spectroscopy or mass
spectrometry. Metagenomics can be used to assess the function
potential.23
Metagenome/metagenomics The collection of all the genomes and genes from all the microbiota
in a given environment. Metagenomics is the process of
characterizing the metagenome through shotgun sequencing of
DNA.23
Metaproteomics
Characterization of the proteins found in a given sample or
environment. Proteins are identified from microbiota, hosts, and

their environment, and computational methods are used to identify
biologic origin.23
Metatranscriptomics
Analysis of meta-RNAs providing information on regulation and
expression profiles of microbiomes.23
Microbiome
The entire ecosystem of microorganisms, their genomes, and their
surrounding environmental and clinical conditions. The term should
not be used to describe data arising from targeted amplicon
sequencing, as it does not contain reliable functional information.23
Microbiota
The collection of individual microbes present in a given sample or at
a specified location. The term can be used to describe composition
and abundance of microbial communities.23
Microflora
Refers to bacteria, fungi, and archaea. Term arose prior to the
restructuring of the domains of life. This term is now considered
incorrect or obsolete as microorganisms are not plants or “flora.” The
term “microbiota” should be used in its place.
Next generation sequencing High-throughput or massively parallel sequencing technology catchall term used to describe modern sequencing methods. NGS has
greater scalability and speed with reduced costs compared with
Sanger sequencing.24
Operational taxonomic units Clusters of sequence reads based on sequence similarity typically
defined as 97% similar. Each cluster is intended to represent a
taxonomic unit of bacteria typically at the genus level when
possible.25
Prebiotic
Fermented or high-fiber foods used by probiotic bacteria to produce
health benefits or to improve the balance of the microbes present.26
Sampling depth
Sometimes called library size. The number of bases sequenced in a
given sample.
Symbiont
An organism living on or within the second, larger organism. Does not
require a functionally significant relationship between the organisms,
though the relationship can be neutral (commensalism), mutualistic
(beneficial to both), or parasitic (beneficial only to the symbiont)
Richness
The number of different species in a given sample.27
Abbreviations: ACE, abundance-based coverage estimator; NSG, next generation sequencing; OUT,
operational taxonomic units.

PROBIOTICS
Probiotics are defined by the Food and Agriculture Organization of the United Nations and the World
Health Organization as live microorganisms that confer a health benefit on the host when administered
in adequate amounts.28 The human body naturally contains many species of probiotic bacteria.
Probiotic bacteria can be used as a dietary supplement aimed at improving health. Most probiotic
products contain live, freeze dried species of Lactobacillus and/or Bifidobacterium. Figure 1 shows the
relationships among these 2 probiotic species to each other and to other commensals, as well as
pathogenic bacteria relevant to perinatal care.

Figure 1.: Bacteria identification. Attribution: Kara Hanson. This figure is available in color online
(www.jpnnjournal.com).

UNDERSTANDING PROBIOTICS
An increasingly popular microbial intervention is the use of probiotics. When discussing probiotics, the
World Health Organization has guidelines for proper identification of probiotic products that are
consistent with those used by the scientific community to identify microorganisms. 28,29 Many have
called for standardization in fast and reliable methods for probiotic identification.30,31 Probiotic strains
are identified by genus, species, and subspecies with an alphanumeric designation for the specific
strain; an example of this is Lactobacillus (genus) acidophilus (species) NCFM (strain).28,29Figure
2 shows the relationship between the taxonomic levels of Lactobacillus acidophilus NCFM.

Figure 2.: Taxonomy of Lactobacillus acidophilus NCFM. Attribution: Kara Hanson. This figure is
available in color online (www.jpnnjournal.com).
Probiotic supplementation is the deliberate ingestion of potentially beneficial
microorganisms. Probiotics work by lining the mucus membranes of the gut to provide a defensive
barrier, promoting the host immune response, stabilizing the gut microbiota, and balancing the proand anti-inflammatory responses.32,33
The most common probiotics in the human body are
genera Lactobacillus and Bifidobacterium.30Lactobacillus belongs to the phylum Firmicutes, which are
gram-positive, nonmotile, non–spore-forming, facultative anaerobic and fermentative
bacteria. Lactobacillus is acid tolerant, so it can survive the digestive processes and is associated with
mucous membranes, such as those found in the GI tract, vagina, and oral cavity.30Bifidobacterium is

gram-positive, nonmotile, non–spore-forming, anaerobic, and heterofermentative.30 The presence,
abundance, and diversity of Bifidobacterium are considered a marker of GI wellness; in
neonates, Bifidobacterium also is associated with gut maturation.6
The genus Lactobacillus has more than 100 species, and of these, 12 are in the Lactobacillus clade and
2 belong to the Pediococcus clade. Lactobacillus has been identified through 16S ribosomal RNA (rRNA)
sequencing (a laboratory technique described later in this article).34Lactobacillus has historically been
used in food preservation in fermented foods, such as in pickled vegetables and
yogurts.30 Probiotics often contain 106 to 109 (1 million to 1 billion) or more colony-forming units per
milliliter (mL), and these bacteria must remain viable in order to offer maximum health benefits to the
host.30Lactobacillus cannot be identified by only colony or cell morphology, but rather by phenotyping,
genotyping, or fermentation properties.30 Examples of phenotyping methods are cell motility testing
and gram staining.30
Probiotics must be able to survive passage from the oral cavity through the GI system to have
maximum potency and benefit.28 One study evaluated 6 different probiotic preparations including
encapsulated pills and yogurt drinks and concluded that Lactobacillus is able to survive acid
environments similar to the human gut.35 Although the mechanism of action is unknown, there is some
evidence that even dead probiotics may offer some immunostimulation; however, it is believed that
there is much greater benefit with a live probiotic.30

PERINATAL-ASSOCIATED MICROBIOTA
The physiologic changes in the perinatal microflora of the oral cavity, gut, placenta, and vagina during
the perinatal period are summarized in Figure 3. The evidence from studies of probiotic interventions
used to modify the microbiota in each site is also discussed.

Figure 3.: Changes in maternal microbiota during pregnancy. From Nuriel-Ohayon et al.36 Reprinted
with permission. This figure is available in color online (www.jpnnjournal.com).

Maternal oral cavity
The oral microbiota includes facultative organisms and strict anaerobes,
including Streptococcus, Bacteroides, Lactobacillus, and more.33 There is a known connection between
maternal periodontal disease and birth outcomes, with higher instances of preterm labor and birth

found in women with periodontal disease. There are no published studies of probiotic interventions
aimed at antenatal oral health, although there is evidence of a relationship between the maternal oral
cavity and the perinatal microbiome.5

Maternal gut
In microbiome research, the term “gut” is used to refer to the entirety of the GI tract. The gut
microbiome has the greatest number of bacteria, estimated at more than 100 trillion. 14 The human gut
has a major role in both immunity and metabolism, and dysbiosis (imbalance in commensal and
pathogenic bacteria) has been linked to adverse health events, such as obesity, diabetes, diarrhea, and
allergic disease.37
Probiotic interventions aimed at altering the gut microflora have been studied during
pregnancy. Probiotics have been shown to colonize the maternal gut during pregnancy and may also
induce a beneficial proinflammatory state.38,39 A proinflammatory state naturally develops in
pregnancy as labor approaches, which is protective for the maternal-neonatal dyad.39 A randomized
controlled trial of prebiotics versus placebo found significantly higher levels of Bifidobacterium in the
maternal gut among those in the probiotics group but no change in the neonatal gut.40 Results are
conflicting regarding the impact of maternal gut colonization with probiotics on neonatal gut
colonization with probiotic bacteria.37,41
The maternal gut is known to be the reservoir for bacteria that colonize the vagina, including group
B Streptococcus (GBS), which has implications for neonates.42,43 More than 20 probiotic bacteria,
mostly Lactobacillus species, have been studied in vitro for antagonist activity against GBS. 44–48 All
showed efficacy in reducing GBS in coculture, indicating that these lactobacilli inhibited the growth of
GBS in laboratory testing using human epithelial cells. The mechanisms of action of the probiotic
bacteria against GBS include acidification/lowering the pH and competitive exclusion. Six clinical trials
of probiotics to reduce antenatal GBS have been published.49–54 The findings of 5 of these studies were
promising and show some efficacy in reducing antenatal GBS colonization or colony counts. 50–53 The
authors of studies in which the efficacy of the probiotic intervention against GBS was not
demonstrated offered possible explanations including the following: the particular probiotic was
ineffective; the dosage was too low; the sample size was too small; and encountering difficulty
recruiting pregnant participants.49,54 More well-controlled studies are needed to determine
effectiveness of probiotic intervention to reduce antenatal GBS.

Vagina
Irrespective of hygiene or sexual practices, organisms that constitute the vaginal microbiota arise from
the maternal gut.55 The GI and genitourinary tracts share some microorganisms, as in the case of GBS,
which colonizes the vagina but primarily is found in the gut.12 Some populations of healthy pregnant
women have less vaginal bacterial diversity than nonpregnant women, and the vagina is dominated
by Lactobacillus species.12 It is possible that this decrease in diversity is protective against other
pathogens.12 Vaginal birth exposes the neonate to both the maternal vaginal microbiota and the rectal
microbiota, likely via a fecal-oral route, colonizing the neonatal gut.56 Neonates born vaginally have
more Lactobacillus species in their meconium than those born by cesarean delivery.57 One randomized
controlled trial of an antenatal probiotic intervention versus placebo showed no significant difference

in vaginal microbiota between the 2 groups.58 More recently, Yang and colleagues59 compared vaginal
microbiota in pregnant women who took a probiotic from 12 weeks' gestation versus controls. They
also found no difference between the groups. More research is needed to identify the possibility of
modifying the vaginal microflora during pregnancy.

Placenta
The placental microbiome is controversial. Historically, the placenta and the uterine environment were
considered to be sterile.60 Aagaard and colleagues61 conducted a recent study of a population-based
cohort of 320 placentas, collected under sterile conditions, and conducted metagenomic studies using
16S rDNA and whole genome shotgun sequencing to compare the placentas with other body sites.
They found that the placenta had a unique microbiome that is most similar to the human oral
cavity.61 Despite this finding, the microbial composition of the placenta remains controversial, with
some scientists arguing that microbes obtained actually represent contamination during specimen
collection.60,62–64 A strong argument has been made for a low biomass (containing limited numbers of
bacteria) fetal and neonatal microbiome.61,65–67 Probiotics may be able to change this biomass; Kaplas
and colleagues68 identified that an antenatal probiotic intervention modified placental phospholipid
fatty acids. Several authors have described the type and importance of collection methods and
emphasized the need for careful collection to avoid contamination.1,5,69 Specimen collection technique
is critical for the clinical staff, who are often obtaining the samples. More research is needed to
understand the relationship between collection, contamination, and the placental microbiome.

Skin and breast
In physiologic births, or births allowed to proceed with no or few obstetric interventions, infants are
placed skin to skin on the maternal chest and the neonate begins breastfeeding. The human axilla is
known to have high microbial biomass, and the breastfed neonate is typically cradled in the mother's
arms in close proximity to the axilla while receiving breast milk.70,71 Breast milk is a synbiotic food,
meaning that it contains both prebiotics and probiotics. There is evidence that probiotics are passed
through breast milk, especially Lactobacillus and Bifidobacterium.37,72 Breastfed neonates have
increased Bifidobacterium in their guts compared with formula-fed neonates. Formula-fed neonates
have increased gut bacterial diversity, including Bacteroides, clostridia, and streptococci, and (fewer)
bifidobacteria.33 Probiotic interventions aimed at altering breast milk composition have been
conducted and antenatal probiotic administration resulted in an increase in antibodies and cytokines in
the breast milk of probiotic group participants compared with controls.73 It has become increasingly
common for infant formula to contain probiotic bacteria in an effort to confer health benefits similar to
breast milk.73

Maternal-fetal dyad
The maternal-neonatal dyad is a dynamic unit; maternal microbiome changes impact the neonate, and
vice versa. The impact of probiotics on the maternal-fetal dyad is a developing science. Microbiome
testing has been conducted on the maternal-fetal dyad to assess similarities and differences.2 Hegde
and Munshi75 sought to examine the relationship between the vaginal microbiota and the neonatal
oral cavity after birth. They found that Staphylococcus epidermidis (typically a commensal skin
bacterium) persisted in the neonatal oral cavity; however, by the termination of the study, the
neonatal oral cavity was dominated by Staphylococcus salivarius (a commensal oral cavity

bacterium).75 This study helped demonstrate that part of the pioneer microbiota of the neonate occurs
following vaginal birth. As previously stated, investigators in one study found similarity between the
placental microbiome and the maternal oral cavity, which may demonstrate an additional route of
colonization for the early perinatal microbiome.61
One longitudinal study of 25 mother-neonate pairs conducted strain-level metagenomic profiling and
followed the pairs from birth to 4 months to document the microbial transition from the mother to the
neonate.2 The study sampled the maternal stool, oral cavity, vagina, skin, and breast milk and the
neonatal stool and oral cavity.2 All of the neonatal pairs shared a large number of gut species with their
mothers, while maternal skin and vaginal strains only temporarily colonized the neonates. 2 The authors
conclude that the maternal gut is the source of the largest number of neonatal microbial strains.2

PURPOSE OF MICROBIOME TESTING/ANALYSIS
Formerly, researchers relied on culture-based methods to study microbes and their
interrelationships.14 As a result, many probiotic interventions available over the counter may be
miscategorized. Huys and colleagues31 found that 28% of the probiotic cultures from 10 different
manufacturers were mislabeled. More than half of the cultures (57%) were from the
genus Lactobacillus, whereas 22% were from the genus Bifidobacterium.31
As mentioned earlier, a number of probiotic interventions have been tested in vitro for efficacy against
specific organisms, such as GBS.44–48 In these studies, the probiotic bacteria are grown in a liquid broth
coculture with bacteria of interest to determine whether the probiotic bacteria can reduce the viability
of the targeted bacteria. This type of testing can be useful before initiating a clinical trial. It can also
yield information about the mechanism of action.
Table 2 compares common approaches to laboratory testing of the microbiome. Significant advances
have been made using laboratory methods that are independent of culture, allowing scientists a
greater understanding of the human microbiome.77 Sanger sequencing was previously the most
common culture independent test used to identify bacterial communities. Sanger sequencing provided
laboratory reads of greater than 500 DNA pairs, whereas newer testing approaches that are described
later give shorter reads of 200 to 400 pairs.14 Sanger sequencing differs from newer approaches by
volume, since the Sanger technique can process only one genome sample at a time whereas next
generation sequencing can simultaneously sequence millions of genes from multiple samples.
Table 2. - Common techniques used to characterize microbiota and the microbiome a
Method
Culture and
culturomics

Description
Isolation of microbes on
selective media. May be
combined with NGS
approaches.

qPCR

Used to amplify and
quantify specific genes.

Advantages
Inexpensive,
semiquantitative,
potential detection of
low abundance
organism
qPCR is quantitative,
both are fast

Limitations
Less than 20% of bacteria
may be identifiable by
culture, though this
number is increasing; labor
intensive
Unable to identify
unknown species, subject
to PCR bias

Microarrays

Targeted
amplicon
sequencing

Whole
genome
shotgun
sequencing

Fluorochrome dyes are
used to label probes that
bind complementary
nucleotides. The
fluorescence emission
pattern is detected by a
laser and used for DNA
identification
Massively parallel, ultradeep sequencing PCR
products (amplicons).
Typically amplification is of
a marker gene such a
portion of the 16S rRNA
gene.
Massively parallel
sequencing of all of the
genomic DNA in a sample.

Semiquantitative, fast

PCR bias and crosshybridization, poor
detection of low
abundance organisms

Quantitative, faster
than shotgun
metagenomics, can
identify unknown
organisms

Poor detection of low
abundance organisms, PCR
bias, somewhat expensive,
genus-level phylogenetic
information only, poor
accuracy for functional
predictions
Most expensive,
computationally intensive
data analysis

Quantitative, high
taxonomic and
functional information,
no PCR bias, strain-level
identification possible
Abbreviation: NSG, next generation sequencing; PCR, polymerase chain reaction; qPCR, quantitative
polymerase chain reaction.
aAdapted from Fraher et al.76

Microbiome analysis is still a new and emerging field and not widely used in all areas of clinical
practice.77 An exception is Fecal Microbiome Transfer that is being applied in clinical care of patients
with unrelenting Clostridium difficile diarrheal infections.78
Microbiome testing is often used in probiotic intervention studies to compare treatment with control
groups. In these studies, probiotics are administered to determine their efficacy at creating health
outcome changes in pregnant women and their neonates.73 Microbial studies can also be used to
determine the adherence to the probiotic intervention. For example, if a probiotic bacterial strain is
found in the stool of a study participant, it is a potential adherence indicator if it was not present
before, providing evidence that the participant took the probiotic. Locating the strain in stool also
provides evidence the probiotic bacteria withstood the acidic environment of the GI tract, an essential
characteristic of any oral probiotic intervention.

COMPARISON OF CONTEMPORARY APPROACHES WITH MICROBIOME
TESTING
The 16S rRNA gene testing is frequently mentioned in the literature and was first introduced in 1985.
This test allows for comparison between bacterial types and genes.1 This approach uses polymerase
chain reaction to target and amplify (regions VI-V9) of the bacterial RNA. The pieces of RNA are called
amplicons. Amplicons from separate samples are coded and pooled together and sequenced, the
process where the nucleic acid order of the nucleotides is determined.77 The 16S rRNA area in bacteria

allows for identification and classification of an area that is exclusive to bacteria. This is because the
ribosomal subunit is a gene that is located on the 30S area of a prokaryotic ribosome; it contains 9
subregions, and each can be targeted for amplification to allow for categorization. 77 16S rRNA contains
a specific region that is unique to each bacterial species, meaning the bacteria can be classified and
also be added to a broad categorization of the species.14 This allows for detection of new microbes and
for comparison between bacterial types and locations, sometimes referred to as niches. 1 The 9 specific
subregions are unique, and different regions better categorize different human microbiome regions.
16S rRNA has some limitations, as the lowest level of taxonomic classification is usually the genus level,
which can limit clinical utility.14 There also are several benefits to 16S rRNA use, including a low rate of
false-positive results and currently it is the least costly approach for microbiome analysis.
Because 16S rRNA is the most common target region for phylogenetic identification, it is often used to
identify members of the genus Lactobacillus.30 16S rRNA and 16S-23S rDNA are tools that allow for
faster identification of probiotics such as Lactobacillus than was possible in the past.30 However, 16S
rRNA does not provide identification of probiotic bacteria to the strain level. This is extremely
important because probiotic benefits are strain dependent.30
Contemporary laboratory methods for microbiome analysis include shotgun sequencing. Unlike 16S
rRNA (that uses only specific genes), shotgun sequencing uses all the DNA genomic material from a
sample. This approach allows for analyses to the strain level and also allows for analysis of metabolic
function and antibiotic resistance analyses. In comparison, deep sequencing provides a higher number
of reads and is a better choice when samples may contain large amounts of host DNA. Deep
sequencing may give more accuracy, but it is more costly.
The use of shotgun analysis is recommended for analyses of human saliva and feces, because it
fragments a large genome into small random DNA fragments that are individually sequenced,
compared by powerful computers for overlaps in the sequences, and then replaces them in their
correct order to reconstitute the genome. There are 2 subtypes of shotgun sequencing: deep and
shallow. Deep shotgun sequencing can be used for general human microbiome analyses. It provides
limited coverage of bacteria, has a high risk of false positive, and is the costliest.79 Shallow shotgun
sequencing has limited bacterial coverage, a high risk of false positives, and is less costly (but still more
costly than 16S rRNA analysis).

DISCUSSION
A comprehensive understanding of perinatal microbiome is an evolving science. The past century has
seen a rapid change in location, type, and interventions associated with birth: from the home to the
hospital environment, from vaginal birth to approximately one-third of US births by cesarean section,
and the use of interventions aimed at improving maternal and neonatal health such as intravenous
intrapartum antibiotic prophylaxis to reduce GBS disease of the newborn. These changes may—or may
not—have implications for the perinatal microbiome and for long-term human health and disease.
Each aspect of the perinatal microbiome, the oral cavity, the GI tract, and the genitourinary tract, may
be susceptible to the influence of microbial interventions. The use of probiotic inventions to improve
health has been the focus of research during the past 20 years. More recently, perinatal researchers

have been studying probiotic interventions to reduce GBS colonization, with the hopes of reducing the
ongoing burden of both GBS disease of the newborn and intrapartum antibiotic use.
As an understanding of the laboratory techniques aimed at evaluating probiotic interventions develop,
the interventions may be targeted to more precisely impact specific areas of the perinatal microbiome.
For example, if specific strains of probiotics are found to be more capable of reducing GBS colonization
in clinical trials, the intervention could be applied in clinical practice. Currently, probiotics may be
found at grocery stores, health food stores, and pharmacies and seem to be increasingly popular.
However, probiotics are not available to women who lack the financial resources to purchase over-thecounter supplements. Probiotics may be an innovative strategy to improve perinatal health; yet,
rigorous studies and methodologies to evaluate their potency and effects are necessary before
clinicians can recommend them.
Laboratory analysis has developed quickly and continues to be increasingly precise and to offer a
greater scope of identification. Although not currently part of routine clinical practice, clinicians must
understand laboratory analysis techniques, both to comprehend the literature and to discuss the
perinatal microbiome with pregnant women and their families.

IMPLICATIONS FOR PERINATAL CLINICIANS AND RESEARCHERS
It is important that perinatal clinicians and researchers become familiar with the laboratory analysis
associated with the microbiome. Clinicians such as nurses and midwives will likely be the scientists
collecting the specimens and will benefit from an understanding of the analysis techniques.
Furthermore, clinicians will be the point of contact for pregnant people and therefore will need to
understand what is known and what is unknown about the perinatal microbiome and which factors
influence it.
At this time, antenatal probiotic interventions are still under investigation and not widely applied to
clinical practice. More well-controlled studies are needed to determine the effectiveness. Ames and
colleagues14 state that microbiome research is currently a descriptive science and few interventions
based on this research are available. However, interventions are emerging; in the perinatal world, one
example of new microbiome research is of probiotics in pregnancy to reduce GBS. As this science
continues to develop, perinatal nurses and midwives may be able to encourage interventions such
as probiotics to improve short- and long-term health.

CONCLUSION
A scientific understanding of the perinatal microbiome is emerging and has the potential to impact
human health and disease. Laboratory analysis of the perinatal microbiome has made great advances
in recent years and is continuing to evolve. As this science develops, interventions such as the use
of probiotics to improve perinatal health will be better understood and therefore may be
recommended by perinatal clinicians.
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